NHE-1 remains a potential therapeutic target for atherosclerosis prevention and treatment despite discouraging results from clinical trials with certain inhibitors.
Answers are grounded in this paper and cite their sources.
NHE-1 inhibitors should not yet enter clinical practice for atherosclerosis; leaves open the target for future trials.
IMPORTANCE OF THE FIELD: The sodium/hydrogen exchanger-1 (NHE-1/SLC9A1) is a ubiquitous plasma membrane protein whose main role is maintenance of intracellular pH and volume. NHE-1 plays a role in atherogenesis; however, its clinical relevance has not yet been established. AREAS COVERED IN THIS REVIEW: We herein review the contribution of NHE-1 in atherogenesis (namely its effect on endothelial cells, monocytes, smooth muscle cells and platelets). WHAT THE READER WILL GAIN: Studies have shown that NHE is involved in atherogenesis-related properties of isolated monocytes. We also consider the relationship between NHE-1 and vascular risk factors such as obesity, diabetes mellitus, hypertension, dyslipidemia and inflammation. TAKE HOME MESSAGE: Even though clinical trials with certain NHE-1 inhibitors have had discouraging results, NHE-1 cannot be excluded as a potential future therapeutic target for the prevention and/or treatment of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Sarigianni et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: